Management of Suspected C. difficile Infection

Diagnosis and Treatment

The World Health Organization and other guideline societies recommend that empirical therapy for C. difficile infection (CDI) should be avoided unless there is strong suspicion for CDI, and diagnostic testing should guide treatment decisions in stable patients with mild-to-moderate suspected CDI 1, 2
Testing should only be performed on diarrheal stools from symptomatic patients with no obvious alternative explanation, and the American Gastroenterological Association recommends testing for CDI in patients with three or more unformed stools in 24 hours 3, 4
The Infectious Diseases Society of America recommends that if a patient has strong suspicion for severe CDI, empirical therapy should be considered while awaiting test results, and the 2019 guidelines explicitly state this as a Recommendation 1C 1, 2
The European Society of Clinical Microbiology and Infectious Diseases recommends looking for clinical features that indicate severity, such as leukocytosis, elevated creatinine, fever, severe abdominal pain and cramping, recent antibiotic use, advanced age, and hospitalization 3, 5
The Society for Healthcare Epidemiology of America recommends implementing contact precautions for patients with suspected or confirmed CDI 3, 5

The American College of Gastroenterology recommends oral vancomycin 125 mg four times daily as the preferred treatment for severe CDI, over metronidazole 1, 2
The International Society for Antimicrobial Chemotherapy recommends fidaxomicin as an alternative first-line option for severe CDI, although metronidazole should be limited to mild-moderate disease only 1, 2

The National Comprehensive Cancer Network recommends empirical treatment with oral vancomycin or metronidazole for neutropenic patients with fever and diarrhea, until diagnostic results are available or if C. difficile infection is strongly suspected clinically 6
The Infectious Diseases Society of America recommends discontinuing offending antibiotics if possible, and switching to agents less frequently associated with CDI if continued antibiotic therapy is required for another infection 1, 2

The risk of overdiagnosis and overtreatment, particularly with highly sensitive tests like NAAT that cannot distinguish colonization from active infection, should be considered when deciding on empirical treatment, according to the World Journal of Emergency Surgery 7
Delayed recognition of alternative causes of diarrheal illness can occur with empirical treatment, as noted in the World Journal of Emergency Surgery 7
Treating based on NAAT-positive results alone without considering clinical context can lead to unnecessary treatment of colonization rather than true infection, affecting up to 7% of asymptomatic hospitalized patients, as reported in the World Journal of Emergency Surgery 7

Delaying treatment in patients with severe disease while awaiting test results can increase mortality risk, as stated in Clinical Infectious Diseases 8
Avoiding repeat testing within 7 days during the same diarrheal episode is recommended, as the diagnostic yield is only approximately 2%, according to Clinical Infectious Diseases 8

Symptomatic patients who have ≥ 3 unformed stools within 24 hours and no obvious alternative cause (e.g., laxatives, tube feeds, other medications) should be tested for C. difficile. [9][10]
Asymptomatic patients, even those with known exposure, should not be tested, because colonization occurs in up to 7 % of hospitalized individuals and does not require treatment. 11

The recommended laboratory strategy is either NAAT alone or a multistep algorithm (GDH + toxin; GDH + toxin arbitrated by NAAT; or NAAT + toxin) when institutional stool‑submission criteria are satisfied. [9][10]

Contact precautions (gloves and gowns) must be instituted immediately upon clinical suspicion, before test results are available. 9

Repeat testing within 7 days of the initial test during the same diarrheal episode provides a low diagnostic yield (≈ 2 %) and should be avoided. 11
Performing a “test of cure” after therapy is not recommended because > 60 % of patients who are clinically cured remain C. difficile PCR‑positive. 11
Do not test or empirically treat asymptomatic patients with known exposure, as this leads to unnecessary antimicrobial use and masks alternative diagnoses. [9][11]